P1517: HUMORAL AND CELLULAR IMMUNE RESPONSES TO SARS-COV-2 NATURAL INFECTION OR VACCINATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A STUDY BY ERIC, THE EUROPEAN RESEARCH INITIATIVE ON CLL
Alessandro Campanella(Vita-Salute San Raffaele University), Paolo Ghia(Vita-Salute San Raffaele University), Massimo Massaia(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Viola Maria Popov(Clinical Emergency Hospital Bucharest), Shai Levi(Tel Aviv Sourasky Medical Center), Yair Herishanu(Tel Aviv University), Emanuela Sant’Antonio(IRCCS Ospedale San Raffaele), Alba Mora(Josep Carreras Leukaemia Research Institute), Quincy Hofsink(Amsterdam Neuroscience), Lydia Scarfò(IRCCS Ospedale San Raffaele), Horia Bumbea(Carol Davila University of Medicine and Pharmacy), Michela Frenquelli(Vita-Salute San Raffaele University), Michael Doubek(Central European Institute of Technology), Κώστας Σταματόπουλος(Centre for Research and Technology Hellas), Sabine Haggenburg(Amsterdam Neuroscience), Maria Colia(IRCCS Ospedale San Raffaele), Eleonora Perotta(IRCCS Ospedale San Raffaele), Carol Moreno(Hospital de Sant Pau), Mette D. Hazenberg(Amsterdam Neuroscience), Magdalena Kättström(Örebro University), Thomas Chatzikonstantinou(G. Papanikolaou General Hospital), Arnon P. Kater(Amsterdam University Medical Centers), Jana Kotašková(Central European Institute of Technology), Filip Vrbacký(Charles University), Silvia Heltai(IRCCS Ospedale San Raffaele), Joanna Zaleska(Medical University of Lublin), Inger S. Nijhof(St. Antonius Ziekenhuis), Elisabetta Albi(University of Perugia), Martin Šimkovič(Charles University), Viviana Roman(Institute of Virology of the Slovak Academy of Sciences), Pamela Ranghetti(IRCCS Ospedale San Raffaele), Krzysztof Giannopoulos(Medical University of Lublin), Salem Al Shimmari(Kuwait University), Catalina Combi(IRCCS Ospedale San Raffaele), Caterina Taccetti(Vita-Salute San Raffaele University), Davide Bisogno(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Ignazio Ezio Tripoli(Department of Medical Sciences), Francesca Martini(University of Pisa), Eloise Scarano(IRCCS Ospedale San Raffaele), Antonella Capasso(IRCCS Ospedale San Raffaele), Christos Demosthenous(G. Papanikolaou General Hospital)
Cited by 0
Related Papers
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907